Table 3.
Treatment-related adverse events occurring in >10% of patients.
| Patients (n = 55) |
|||
|---|---|---|---|
| Any grade, n (%) | Grade 1–2, n (%) | Grade 3–4, n (%) | |
| Any adverse event | 55 (100%) | 31 (56.3%) | 24 (43.6%) |
| Elevated AST | 36 (65.5%) | 25 (45.5%) | 11 (20.0%) |
| Elevated ALT | 34 (61.8%) | 27 (49.1%) | 7 (12.7%) |
| Pyrexia | 25 (45.5%) | 21 (38.2%) | 4 (7.3%) |
| Lymphopenia | 22 (40.0%) | 18 (32.7%) | 4 (7.3%) |
| Electrolytes disorder | 21 (38.2%) | 20 (36.4%) | 1 (1.8%) |
| Hypoalbuminemia | 21 (38.2%) | 21 (38.2%) | 0 |
| Anaemia | 20 (36.4%) | 18 (32.7%) | 2 (3.6%) |
| Thrombocytopenia | 20 (36.4%) | 18 (36.3%) | 2 (3.6%) |
| Elevated GGT | 19 (34.5%) | 18 (32.7%) | 1 (1.8%) |
| Fatigue | 18 (32.7%) | 18 (32.7%) | 0 |
| Nausea | 18 (32.7%) | 18 (32.7%) | 0 |
| Abdominal pain | 15 (27.3%) | 15 (27.3%) | 0 |
| Hypothyroidism | 15 (27.3%) | 15 (27.3%) | 0 |
| Leucocytosis | 15 (27.3%) | 15 (27.3%) | 0 |
| Vomiting | 14 (25.5%) | 14 (25.5%) | 0 |
| Elevated ALP | 14 (25.5%) | 14 (25.5%) | 0 |
| Leukocytopenia | 13 (23.6%) | 13 (23.6%) | 0 |
| Hyperbilirubinemia | 12 (21.8%) | 11 (20.0%) | 1 (1.8%) |
| Elevated PT | 11 (20.0%) | 11 (20.0%) | 0 |
| Shiver | 9 (16.4%) | 9 (16.4%) | 0 |
| Cough | 7 (12.7%) | 7 (12.7%) | 0 |
| RCCEP | 7 (12.7%) | 7 (12.7%) | 0 |
| Stress hyperglycaemia | 7 (12.7%) | 7 (12.7%) | 0 |
| Hypertension | 6 (10.9%) | 6 (10.9%) | 0 |
| Arrhythmias | 6 (10.9%) | 6 (10.9%) | 0 |
AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; PT, prothrombin time; RCCEP, reactive cutaneous capillary endothelial proliferation.